-
Interference with ERK-dimerization at the nucleocytosolic interface targets pathological ERK1/2 signaling without cardiotoxic side-effects2020 Nature Communications article Biochemistry, Genetics and Molecular Biology Melanoma and MAPK Pathways Open access
Angela Tomasovic, Theresa Brand, Constanze Schanbacher, Sofia Kramer, Martin W. Hümmert, Patrício Godoy, +19 more
63citations -
Phase 1 study of the pan-HER inhibitor dacomitinib plus the MEK1/2 inhibitor PD-0325901 in patients with KRAS-mutation-positive colorectal, non-small-cell lung and pancreatic cancer2020 British Journal of Cancer article Biochemistry, Genetics and Molecular Biology Melanoma and MAPK Pathways Open access
Robin M.J.M. van Geel, Emilie M.J. van Brummelen, Ferry A.L.M. Eskens, Sanne C.F.A. Huijberts, Filip De Vos, Martijn P. Lolkema, +11 more
57citations -
Neoadjuvant Cytoreductive Treatment With BRAF/MEK Inhibition of Prior Unresectable Regionally Advanced Melanoma to Allow Complete Surgical Resection, REDUCTOR2021 Annals of Surgery article Biochemistry, Genetics and Molecular Biology Melanoma and MAPK Pathways Open access
Stéphanie A. Blankenstein, Maartje W. Rohaan, W. Martin C. Klop, Bernies van der Hiel, Bart A. van de Wiel, Max J. Lahaye, +11 more
48citations -
Age Does Matter in Adolescents and Young Adults versus Older Adults with Advanced Melanoma; A National Cohort Study Comparing Tumor Characteristics, Treatment Pattern, Toxicity and Response2020 Cancers article Biochemistry, Genetics and Molecular Biology Melanoma and MAPK Pathways Open access
Monique K. van der Kooij, Marjolein J.A.L. Wetzels, Maureen J.B. Aarts, Franchette W.P.J. van den Berkmortel, Christian U. Blank, Marye J. Boers‐Sonderen, +14 more
44citations -
Mechanisms of Melanoma Progression and Treatment Resistance: Role of Cancer Stem-like Cells2024 Cancers article Biochemistry, Genetics and Molecular Biology Melanoma and MAPK Pathways Open access
Youssef Al Hmada, Robert Thomas Brodell, Naji Kharouf, Thomas Wayne Flanagan, Abdulhadi A. AlAmodi, Sofie-Yasmin Hassan, +6 more
40citations -
Persister state-directed transitioning and vulnerability in melanoma2022 Nature Communications article Biochemistry, Genetics and Molecular Biology Melanoma and MAPK Pathways Open access
Heike Chauvistré, Batool Shannan, Sheena M. Daignault-Mill, Robert J. Ju, Daniel J. Picard, Stefanie Egetemaier, +30 more
35citations -
Long-term survival of patients with advanced melanoma treated with BRAF-MEK inhibitors2022 Melanoma Research article Biochemistry, Genetics and Molecular Biology Melanoma and MAPK Pathways Open access
Rawa Kamaran Ismail, Karijn P.M. Suijkerbuijk, Anthonius de Boer, Maaike van Dartel, Doranne L. Hilarius, Anna M.G. Pasmooij, +16 more
32citations -
First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAFV600-mutant advanced melanoma patients: a propensity-matched survival analysis2021 British Journal of Cancer article Biochemistry, Genetics and Molecular Biology Melanoma and MAPK Pathways Open access
Jesper van Breeschoten, Michel W.J.M. Wouters, Doranne L. Hilarius, John B.A.G. Haanen, Christian U. Blank, Maureen J.B. Aarts, +13 more
27citations -
Analysis of CRISPR‐Cas9 screens identifies genetic dependencies in melanoma2020 Pigment Cell & Melanoma Research article Biochemistry, Genetics and Molecular Biology Melanoma and MAPK Pathways Open access
Eirini Christodoulou, Mamunur Rashid, Clare Pacini, Alastair Droop, Holly Robertson, Tim van Groningen, +5 more
25citations -
Loss of Wild-Type CDKN2A Is an Early Event in the Development of Melanoma in FAMMM Syndrome2020 Journal of Investigative Dermatology article Biochemistry, Genetics and Molecular Biology Melanoma and MAPK Pathways Open access
Eirini Christodoulou, Rogier J. Nell, Robert M. Verdijk, Nelleke A. Gruis, Pieter A. van der Velden, Remco van Doorn
17citations -
IMPemBra: a phase 2 study comparing pembrolizumab with intermittent/short-term dual MAPK pathway inhibition plus pembrolizumab in patients with melanoma harboring the BRAFV600 mutation2023 Journal for ImmunoTherapy of Cancer article Biochemistry, Genetics and Molecular Biology Melanoma and MAPK Pathways Open access
Elisa A. Rozeman, Judith M. Versluis, Karolina Sikorska, Esmée P. Hoefsmit, Petros Dimitriadis, Disha Rao, +15 more
17citations -
Mutually exclusive genetic interactions and gene essentiality shape the genomic landscape of primary melanoma2022 The Journal of Pathology article Biochemistry, Genetics and Molecular Biology Melanoma and MAPK Pathways Open access
Sofia Birkeälv, Mark Harland, Larissa Satiko Alcântara Sekimoto Matsuyama, Ishan Mehta, Jonathan P. Laye, Kerstin Haase, +11 more
16citations -
Adjuvant BRAF-MEK Inhibitors versus Anti PD-1 Therapy in Stage III Melanoma: A Propensity-Matched Outcome Analysis2023 Cancers article Biochemistry, Genetics and Molecular Biology Melanoma and MAPK Pathways Open access
Melissa Melanie de Meza, Willeke A.M. Blokx, Johannes J. Bonenkamp, Christian U. Blank, Maureen J.B. Aarts, Franchette W.P.J. van den Berkmortel, +14 more
16citations -
BRAF/MEK inhibitor rechallenge in advanced melanoma patients2024 Cancer article Biochemistry, Genetics and Molecular Biology Melanoma and MAPK Pathways Open access
Olivier J. van Not, Alfons J.M. van den Eertwegh, John B.A.G. Haanen, Rozemarijn S. van Rijn, Maureen J.B. Aarts, Franchette W.P.J. van den Berkmortel, +13 more
16citations -
Clinical outcomes and genomic profiles of MAP2K1-mutated primary cutaneous melanocytic tumours2025 EBioMedicine article Biochemistry, Genetics and Molecular Biology Melanoma and MAPK Pathways Open access
Chiel F Ebbelaar, Anne M.L. Jansen, Leonie C M Speet, Frans Schutgens, Sietske Zoetemeyer, Anne‐Marie Cleton-Jansen, +8 more
9citations -
Efficacy of BRAF and MEK Inhibition in Patients with BRAF-Mutant Advanced Melanoma and Germline CDKN2A Pathogenic Variants2021 Cancers article Biochemistry, Genetics and Molecular Biology Melanoma and MAPK Pathways Open access
Francesco Spagnolo, Bruna Dalmasso, Enrica T. Tanda, Míriam Potrony, Susana Puig, Remco van Doorn, +4 more
9citations -
Efficacy of encorafenib plus binimetinib in patients with BRAF-mutated melanoma brain metastases: Results from the Dutch Melanoma Treatment Registry2025 European Journal of Cancer article Biochemistry, Genetics and Molecular Biology Melanoma and MAPK Pathways Open access
Karijn P.M. Suijkerbuijk, Maureen J Aarts, Franchette W.P.J. van den Berkmortel, C.U. Blank, Willeke A.M. Blokx, Marye J. Boers‐Sonderen, +13 more
7citations -
Persister state-directed transitioning and vulnerability in melanoma2020 bioRxiv (Cold Spring Harbor Laboratory) preprint Biochemistry, Genetics and Molecular Biology Melanoma and MAPK Pathways Open access
Heike Chauvistré, Batool Shannan, Sheena M. Daignault, Robert J. Ju, Daniel J. Picard, Stefanie Egetemaier, +28 more
4citations -
A distinct four-value blood signature of pyrexia under combination therapy of malignant melanoma with dabrafenib and trametinib evidenced by an algorithm-defined pyrexia score2022 PLoS ONE article Biochemistry, Genetics and Molecular Biology Melanoma and MAPK Pathways Open access
Hannah Schaefer, Albert Rübben, André Esser, Arturo Araujo, Oana‐Diana Persa, Marike M. Leijs
3citations -
Nationwide Outcomes of Advanced Melanoma According to BRAFV600 Status2020 American Journal of Clinical Oncology article Biochemistry, Genetics and Molecular Biology Melanoma and MAPK Pathways Open access
Jesper van Breeschoten, Michel W.J.M. Wouters, Liesbeth C. de Wreede, Doranne L. Hilarius, John B.A.G. Haanen, Christian U. Blank, +14 more
3citations -
The Predictive Value of FDG PET/CT for Determining Progression-Free Survival in Advanced Stage III–IV BRAF-Mutated Melanoma Patients Treated With Targeted Therapy—What Can Be Learned From Progression?2023 Clinical Nuclear Medicine article Biochemistry, Genetics and Molecular Biology Melanoma and MAPK Pathways Open access
Bernies van der Hiel, Else A. Aalbersberg, Alfons J.M. van den Eertwegh, Berlinda J. de Wit–van der Veen, Marcel P. M. Stokkel, Marta López‐Yurda, +9 more
3citations -
Adjuvant BRAF/MEK versus anti-PD-1 in BRAF-mutant melanoma: a propensity score matched survival analysis2025 British Journal of Cancer article Biochemistry, Genetics and Molecular Biology Melanoma and MAPK Pathways Open access
Manja Bloem, Melissa Melanie de Meza, Alfons J.M. van den Eertwegh, Maureen J.B. Aarts, Franchette W.P.J. van den Berkmortel, Christian U. Blank, +16 more
3citations -
Phase I study of afatinib plus selumetinib in patients with KRAS mutation-positive colorectal, non-small cell lung and pancreatic cancer.2020 Journal of Clinical Oncology conference-abstract Biochemistry, Genetics and Molecular Biology Melanoma and MAPK Pathways
Sanne C.F.A. Huijberts, Emilie M.J. van Brummelen, Carla M.L. van Herpen, Ingrid M.E. Desar, Frans L. Opdam, Robin M.J.M. van Geel, +9 more
3citations -
Adjuvant BRAF/MEK versus anti-PD-1 in BRAF-mutant melanoma: Propensity score–matched recurrence-free, distant metastasis-free, and overall survival analysis.2024 Journal of Clinical Oncology conference-abstract Biochemistry, Genetics and Molecular Biology Melanoma and MAPK Pathways
Manja Bloem, Melissa Melanie de Meza, Maureen J.B. Aarts, Franchette van den Berkmortel, Christian U. Blank, Willeke A.M. Blokx, +14 more
3citations